Niacinamide: Dual Benefits for Skin Cancer Prevention and Heart Health

A recent 2025 study reveals that the same oral supplement dermatologists often prescribe to prevent non-melanoma skin cancers may also slash the risk of serious heart events, including a 45% lower chance of ST-elevation myocardial infarction.

Key Areas We Will Cover

• How niacinamide supports skin cancer prevention in high-risk patients
• The 2025 TriNetX study linking niacinamide to reduced cardiovascular risks
• Specific heart event reductions observed, including STEMI, peripheral vascular disease, and cardiac arrest
• Why do these findings reassure dermatologists and patients in the UK
• Safety profile, dosing recommendations, and who benefits most
• Integrating niacinamide with sun protection and regular checks

Introduction

Niacinamide, a form of vitamin B3, has long been valued in dermatology for its role in non-melanoma skin cancer prevention, helping repair UV-induced DNA damage and bolster skin immunity. A compelling 2025 retrospective cohort study now highlights additional cardiovascular advantages, addressing past concerns about niacin metabolites and heart risks. For UK patients, where non-melanoma skin cancers exceed 150,000 cases yearly, and cardiovascular disease remains a leading concern, this dual benefit underscores the value of consulting a dermatologist to explore niacinamide as part of a comprehensive skin and overall health strategy.

Understanding Niacinamide’s Established Role in Skin Cancer Prevention

Niacinamide works by replenishing cellular NAD+ levels, enhancing DNA repair, and countering UV-induced immunosuppression.

• Proven Efficacy: Landmark trials, including the 2015 ONTRAC study, demonstrated a 23% reduction in new non-melanoma skin cancers among high-risk individuals taking 500 mg twice daily.
• Recent Large-Scale Evidence: 2025 veteran cohort analyses reported up to 54% risk reduction when initiated after a first skin cancer diagnosis, particularly for squamous cell carcinoma.
• UK Context: With rising cases linked to cumulative sun exposure, dermatologists frequently recommend niacinamide for patients with multiple actinic keratoses, prior tumours, or immunosuppression, complementing broad-spectrum sunscreen and annual screenings.

Competitor content often emphasises skin benefits alone, overlooking emerging heart protections that enhance its appeal for older adults.

Breakthrough 2025 Findings: Lower Cardiovascular Event Risk

Published in the Journal of the American Academy of Dermatology, this TriNetX database study compared 3,231 patients taking oral niacinamide (≥500 mg daily) for non-melanoma skin cancer prevention or bullous pemphigoid against matched controls.

Study Design Highlights

• Participants averaged 71.6 years old, mostly male (58.8%) and White (87.9%).
• Median follow-up: 912 days for niacinamide users, 1,095 days for controls.
• Outcomes tracked: Major adverse cardiovascular events, including STEMI, non-STEMI, stroke, transient ischaemic attack, peripheral vascular disease, acute coronary syndromes, and cardiac arrest.

Results countered earlier metabolite concerns, showing protective associations instead.

Specific Cardiovascular Risk Reductions

Niacinamide users experienced notable declines in several events:

• ST-Elevation Myocardial Infarction (STEMI): 45% lower risk (0.9% vs 1.6%; risk ratio 0.547, P=0.008).
• Peripheral Vascular Disease: 26% lower risk (4.7% vs 6.3%; risk ratio 0.741, P=0.004).
• Cardiac Arrest: 50% lower risk (0.5% vs 1.0%; risk ratio 0.500, P=0.020).

No significant differences appeared for non-STEMI, stroke, transient ischaemic attack, or overall acute coronary syndromes in the main cohort.

Subgroup Advantages

• No Prior Atherosclerotic Disease: Marked reductions in strokes (57% lower), transient ischaemic attacks (58% lower), and acute coronary syndromes (49% lower).
• With Prior Heart Disease: Even stronger protections, including 51% lower STEMI risk and benefits across multiple outcomes.

These outcomes support niacinamide’s safety for dermatology patients, many of whom face overlapping age-related risks.

Who Benefits Most from Niacinamide?

Ideal candidates include:

• Those with multiple non-melanoma skin cancers or precancerous lesions.
• Older adults (typically over 70) with UV damage history.
• Immunosuppressed individuals, such as transplant recipients (though benefits vary).
• Patients are concerned about both skin cancer recurrence and cardiovascular health.

Dosing usually starts at 500 mg twice daily; a dermatologist can tailor this based on individual factors.

Safety Profile and Practical Considerations

Niacinamide offers a strong safety record compared to niacin, with minimal flushing.

• Common Side Effects: Occasional mild stomach upset; rare headaches.
• Study Limitations: Retrospective nature may include confounding; predominantly White cohort; shorter follow-up.
• UK Guidance: Aligns with high-risk chemoprevention; combine with SPF 50+, gentle skincare, and routine mole checks.

Competitors rarely integrate these heart findings, creating an opportunity to position niacinamide as a multifaceted option.

Conclusion

The 2025 TriNetX study affirms niacinamide’s value for non-melanoma skin cancer prevention while revealing reassuring cardiovascular protections, such as reduced risks of STEMI, peripheral vascular disease, and cardiac arrest. These insights empower UK patients to address dual threats through evidence-based supplementation under dermatologist guidance. Key points include its accessibility, favourable safety, and potential to enhance both skin resilience and heart wellbeing.

Take Control of Your Skin and Heart Health Today

Ready to discuss niacinamide for skin cancer prevention and potential heart benefits? Book a consultation with a dermatologist at The Skin Care Network, 68-70 Union St, Barnet EN5 4HZ, United Kingdom. Call +44 20 8441 1043 or request an appointment online for a personalised assessment and advice.